News
Hims & Hers has risen 70% since November 2024, outperforming the S&P 500, despite recent regulatory challenges impacting its compounded semaglutide ... The chart below shows that this metric ...
Hosted on MSN1mon
Hims & Hers can't sell off-brand Ozempic forever. But it can still sell these weight loss drugsOn Monday’s call, Hims & Hers CFO Oluyemi Okupe said that personalized semaglutide dosages will supplement the company’s core offerings. The company announced in November that it plans to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback